– Advances lead product into clinic and additional compounds into
– David Mauro, MD, PhD, as Chief Medical Officer, and Brian Piper,
MBA, as Chief Financial Officer, join management team led by Founder and
CEO, Kris Vaddi, PhD
WILMINGTON, Del.–(BUSINESS WIRE)–Prelude Therapeutics, a privately held, clinical-stage biopharmaceutical
company focused on the discovery and development of small molecule drugs
that target key drivers of cancer cell growth, survival and resistance,
secured $60 million in Series B financing; taking its total investments
to date to $95 million. The financing was co-led by Prelude’s two
existing institutional investors, including OrbiMed Advisors LLC.
Since its launch in July 2016, Prelude has made rapid progress in its
first discovery program targeting Protein Arginine Methyltransferase 5
(PRMT5), a member of the arginine methyltransferase family. PRMT5 plays
an important role in several cellular processes that drive cancer cell
proliferation, cell cycle progression and resistance to apoptosis in
hematological malignancies and solid tumors.
Proceeds from the Series B financing will be used to advance Prelude’s
proprietary PRMT5 inhibitor, PRT543, through proof of concept clinical
studies. PRT543 is in a parallel dose escalation Phase 1 clinical trial
for solid tumors, myeloid malignancies and lymphomas.
Series B funding will also be used to advance additional differentiated
compounds from the PRMT5 program and strengthen Prelude’s discovery,
preclinical and clinical development infrastructure to support a rapidly
advancing pipeline beyond PRMT5. Prelude has established several drug
discovery programs and compounds from these early-stage programs are
also expected to enter preclinical development in the second half of
2019 with a potential IND-filing in 2020.
“We are very appreciative of the continued support of our current
investors, who have been integral to the founding of Prelude and the
creation of our growing pipeline,” said Kris Vaddi, PhD, Founder and CEO
of Prelude Therapeutics. “We believe PRMT5 inhibitors represent a
promising new class of drugs to treat cancers, including ones that have
developed resistance to existing targeted therapies. We are also pleased
to have assembled such a talented, experienced and proven leadership
team to address some of the most pressing gaps in cancer treatment.”
Prelude Management Team
Dr. Vaddi founded Prelude in July 2016 and serves as CEO and a member of
the Board of Directors. Prior to Prelude, Dr. Vaddi was a member of the
founding team of Incyte Corporation in 2002 and most recently served as
a group vice president. He initiated and championed JAK research
programs at Incyte that led to the discovery, development and approval
of Jakafi® (ruxolotinib) for Myelofibrosis and Polycythemia
Vera and Olumiant® (Baricitinib) for rheumatoid arthritis.
Dr. Vaddi received his Doctorate in Veterinary Medicine from APAU in
India and his PhD from the University of Florida.
On May 1, 2019, David Mauro, MD, PhD, was named Chief Medical Officer.
Dr. Mauro comes to Prelude with strong drug development experience in
positions of increasing responsibility at Bristol-Myers Squibb, Merck
and most recently Checkmate Pharmaceuticals as its Chief Medical
Officer. Dr. Mauro earned his MD and PhD from Temple University School
Beginning July 1, 2019, Brian Piper, MBA will join Prelude as Chief
Financial Officer. Mr. Piper most recently served as Chief Financial
Officer at Aevi Genomic Medicine, where he was responsible for
leadership and management of corporate financing and reporting,
corporate fundraising efforts and investor relations. Prior to that, Mr.
Piper held roles of increasing responsibility in finance, program and
alliance management and investor relations at Shire Pharmaceuticals.
About Prelude Therapeutics
Prelude Therapeutics is a privately held, clinical-stage
biopharmaceutical company based in Wilmington, DE. Prelude is focused on
the discovery and development of small molecule agents targeting novel
molecular mechanisms that drive cancer cell growth, survival and
resistance to current treatments. For more information, please visit www.preludetx.com.
Sam Brown Inc. Healthcare Communications